Galaxy Surfactants (NSE: GALAXYSURF) Q3 FY26 results signal portfolio resilience as specialty growth offsets global surfactant pressures
Natural Capsules (NSE: NATCAPSUQ) Q3 FY26 results signal operational recovery after regulatory shock, but fermentation execution risk still looms
Read More 5 minute read Pharma Industry News Etalanetug shows over 90% tau biomarker reduction in Eisai’s DIAD trial update at CTAD 2025 Eisai’s etalanetug shows up to 90% reduction in novel tau biomarker in Alzheimer’s patients. Find out how it could reshape the AD treatment landscape. bySrinathDecember 2, 2025